| Han, Weidong |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT04510610: Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma |
|
|
| Recruiting | 2/3 | 100 | RoW | Camrelizumab and Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 01/22 | 01/25 | | |
NCT02159820: Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer |
|
|
| Recruiting | 2/3 | 500 | RoW | Decitabine (DTC Arm), Paclitaxel and Carboplatin (TC Arm) | Chinese PLA General Hospital | Primary Malignant Neoplasm of Ovary, FIGO Stages II to IV | 06/24 | 06/24 | | |
NCT03989336: A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
|
|
| Completed | 2 | 84 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Platinum chemotherapy, Sintilimab, anti-PD-1 antibody; PD-1 inhibitor | Chinese PLA General Hospital | Ovarian Cancer | 05/22 | 12/23 | | |
NCT03250962: SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 280 | RoW | SHR-1210, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 07/22 | 03/25 | | |
NCT04514081: The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. |
|
|
| Recruiting | 2 | 200 | RoW | Chidamide; Decitabine; Camrelizumab, Decitabine+Camrelizumab | Chinese PLA General Hospital | Hodgkin Lymphoma, Anti-PD-1 Antibody Resistant | 08/22 | 08/25 | | |
NCT05073250: IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. |
|
|
| Recruiting | 2 | 40 | RoW | IBI376, PI3Kδ inhibitor, Rituximab, Anti-cluster of differentiation antigen 20 (CD20) monoclonal antibody | Chinese PLA General Hospital | Inert Non Hodgkin's Lymphoma | 12/23 | 11/24 | | |
CHN-PLAGH-BT-045, NCT04233294: Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 100 | RoW | Chidamide, Camrelizumab, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 02/24 | 02/26 | | |
NCT06393361: Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. |
|
|
| Recruiting | 2 | 100 | RoW | Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody. | Chinese PLA General Hospital | Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma | 06/26 | 06/27 | | |
ZARAV, NCT06471738: Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma |
|
|
| Recruiting | 2 | 30 | RoW | Zanubrutinib, Rituximab, Venetoclax | Chinese PLA General Hospital | Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma | 12/26 | 06/27 | | |
NCT06558773: GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. |
|
|
| Not yet recruiting | 2 | 120 | RoW | Eliglustat+Immune checkpoint inhibitor+Regorafenib, Regorafenib(Stivarga), Eliglustat(Cerdelga), Eliglustat+Immune checkpoint inhibitor, Regorafenib+Immune checkpoint inhibitor | Chinese PLA General Hospital | Colorectal Cancer | 08/26 | 08/27 | | |
NCT02259556: CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas |
|
|
| Recruiting | 1/2 | 30 | RoW | CART30, anti-CD30 CAR T cells | Chinese PLA General Hospital | Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | 10/18 | 10/29 | | |
NCT03989310: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 50 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Gemcitabine, anti-PD-1 antibody, Anti-PD-1 monoclonal antibody; PD-1 inhibitor | Chinese PLA General Hospital | Pancreatic Cancer | 05/21 | 03/22 | | |
NCT04553393: Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden |
|
|
| Recruiting | 1/2 | 80 | RoW | Chidamide, cohort 2, Decitabine, cohort 3, Chidamide and Decitabine, cohort 4, Decitabine-primed Tandem CAR19/20 engineered T cells, cohort 1 | Chinese PLA General Hospital | Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden | 09/21 | 09/22 | | |
NCT04588324: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 50 | RoW | SHR2150, Anti-Cancer Agent | Chinese PLA General Hospital | Solid Tumor | 11/21 | 11/22 | | |
NCT04897477: Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | Azacytidine, Bendamustine and Piamprizumab | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 04/22 | 04/23 | | |
NCT04873440: An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma |
|
|
| Recruiting | 1/2 | 10 | RoW | Manganese Chloride, Mn2+, Radiotherapy, Chemo-immunotherapy | Chinese PLA General Hospital | Solid Tumor, Lymphoma | 05/22 | 05/23 | | |
NCT03754764: A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy |
|
|
| Recruiting | 1/2 | 80 | RoW | Specificity CD38 CAR-T Cells | Chinese PLA General Hospital | Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI | 11/22 | 11/22 | | |
NCT03767751: A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 80 | RoW | Dual Specificity CD38 and bcma CAR-T Cells | Chinese PLA General Hospital | Multiple Myeloma | 12/22 | 12/22 | | |
NCT04082910: Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells |
|
|
| Recruiting | 1/2 | 30 | RoW | Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents | Chinese PLA General Hospital | Solid Tumor, Hematological Malignancy | 12/22 | 12/23 | | |
NCT04407741: Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas |
|
|
| Recruiting | 1/2 | 100 | RoW | SHR2554+SHR1701, SHR1701 | Chinese PLA General Hospital | Solid Tumor, Lymphoma | 12/24 | 12/25 | | |
NCT04764513: Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT |
|
|
| Recruiting | 1/2 | 20 | RoW | Ex-vivo expanded γδ T cell infusion, Chemotherapy | Chinese PLA General Hospital | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Lymphoma | 04/23 | 04/25 | | |
NCT05327582: An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC |
|
|
| Recruiting | 1/2 | 65 | RoW | Durvalumab, Lenvatinib, Nab paclitaxel | Chinese PLA General Hospital | Pancreatic Cancer, Biliary Tract Cancer | 04/23 | 04/24 | | |
NCT04697940: Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL |
|
|
| Recruiting | 1/2 | 33 | RoW | Decitabine-primed Tandem CAR19/20 engineered T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Han weidong | Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells | 12/24 | 12/25 | | |
NCT04765462: Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors |
|
|
| Recruiting | 1/2 | 60 | RoW | Allogeneic γδ T cells | Chinese PLA General Hospital | Malignant Solid Tumours | 12/23 | 12/24 | | |
NCT06321289: Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | Allogeneic CD19-STAR T cell, Allogeneic CD19-targeting synthetic T-cell receptor antigen receptor T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 03/26 | 03/27 | | |
NCT05320640: Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 100 | RoW | Chidamide, Decitabine, Immune checkpoint inhibitors（anti-PD1/PD-L1/CTLA4 antibodies） | Chinese PLA General Hospital | Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors | 04/24 | 04/25 | | |
NCT04337606: Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor |
|
|
| Recruiting | 1/2 | 100 | RoW | Chidamide, Decitabine, Camrelizumab | Chinese PLA General Hospital | Non Hodgkin Lymphoma | 04/24 | 04/26 | | |
NCT06323525: TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T), Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma | 04/26 | 04/27 | | |
| Recruiting | 1/2 | 120 | RoW | Chidamide, HDACi, Fludarabine and cyclophosphamide, FC regimen, Anti-CD19 CAR-T cells, Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cells | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 06/24 | 06/25 | | |
NCT05631912: TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 38 | RoW | Autologous CD19-STAR-T cell, Autologous CD19-targeting synthetic T-cell receptor antigen receptor T cells, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non-hodgkin Lymphoma,B Cell | 12/24 | 12/25 | | |
NCT05554939: Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | Allogenic CD19-CAR-γδT cell, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 12/25 | 12/26 | | |
NCT05693844: Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 15 | RoW | Pan-T booster co-expressing MSLN CAR T cell, Albumin-bound paclitaxel, Cyclophosphamide, Fludarabine | Chinese PLA General Hospital, UTC Therapeutics Inc. | Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
NCT06481735: TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL |
|
|
| Recruiting | 1/2 | 30 | RoW | TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell, Allogeneic Power3 knock-out CD19 CAR-T, Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital, Peking University | Acute Lymphocytic Leukemia | 02/27 | 02/28 | | |
NCT06014073: TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T), Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital, Peking University, EdiGene Inc. | Non Hodgkin's Lymphoma | 09/25 | 09/26 | | |
NCT05699811: IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 40 | RoW | MSC-IFNα, Nab paclitaxel, Abraxane, Cyclophosphamide, Anti-PD-1 monoclonal antibody, Toripalimab Injection, Sintilimab Injection, Camrelizumab Injection, Tislelizumab Injection | Chinese PLA General Hospital, Wuxi Sinotide New Drug Discovery Institutes | Locally Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
NCT05948033: CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | CD70-targeting CAR-T cells | Chinese PLA General Hospital, UTC Therapeutics Inc. | Lymphoma | 12/25 | 12/26 | | |
NCT05947487: CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 30 | RoW | CD70-targeting CAR-T cells | Chinese PLA General Hospital, UTC Therapeutics Inc. | Solid Tumor, Adult | 12/25 | 12/26 | | |
NCT04976218: TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | TGFβR-KO CAR-EGFR T Cells | Chinese PLA General Hospital | Solid Tumor, Adult, EGFR Overexpression | 12/23 | 12/24 | | |
NCT04944888: GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor |
|
|
| Completed | 1 | 31 | RoW | Eliglustat, Immune checkpoint inhibitor | Chinese PLA General Hospital | Solid Tumor, Hematologic Malignancy | 11/23 | 11/23 | | |
NCT05631899: CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 15 | RoW | KRAS-EphA-2-CAR-DC, Abraxane, Abraxane Injectable Product, Cyclophosphamide, Cyclophosphamide for Injection, Anti-PD-1 antibody, PD-1 blocking antibody, Anti-CTLA4 Monoclonal Antibody, Ipilimumab | Chinese PLA General Hospital, Zhejiang University | Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C, KRAS G12D | 12/25 | 12/26 | | |
NCT05631886: Combination of CAR-DC Vaccine and ICIs in Malignant Tumors |
|
|
| Recruiting | 1 | 10 | RoW | TP53-EphA-2-CAR-DC, Abraxane, Abraxane Injectable Product, Cyclophosphamide, Cyclophosphamide for Injection, anti-PD-1 antibody, PD-1 blocking antibody, Anti-CTLA4 Monoclonal Antibody, Ipilimumab | Chinese PLA General Hospital, Zhejiang University | Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H, TP53 R175H, TP53 R248Q, TP53 R249S | 12/25 | 12/26 | | |
| Recruiting | N/A | 205 | RoW | artificial intelligence prediction system, the radiologists | Sixth Affiliated Hospital, Sun Yat-sen University, Sir Run Run Shaw Hospital, The Third Affiliated Hospital of Kunming Medical College. | Rectal Cancer | 12/22 | 03/23 | | |
NCT06079242: Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 200 | RoW | Resin microspheres containing yttrium-90 (Y-90), SIR-Spheres® Y-90 | GrandPharma (China) Co., Ltd. | Colorectal Neoplasms | 12/26 | 04/27 | | |
| Not yet recruiting | N/A | 400 | RoW | Artificial Intelligence | Sixth Affiliated Hospital, Sun Yat-sen University | Pelvic Cancer | 06/24 | 08/24 | | |
| Yan, Sheng |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT05760430: The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
|
|
| Recruiting | 1 | 30 | RoW | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital | HCC | 12/26 | 06/27 | | |
NCT06164769: Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery |
|
|
| Recruiting | N/A | 30 | RoW | blocking both the abdominal trunk and superior mesenteric artery in the pancreatic enucleation | Zhejiang University | Tumor of Pancreas, Surgical Blood Loss | 05/26 | 06/26 | | |
NCT06415643: The Use of Islet Organoids in the Treatment of Pancreatic Surgery-related Diabetes |
|
|
| Recruiting | N/A | 5 | RoW | Islet organoids transplantation | Zhejiang University, Newislet Biotechnology (Shanghai) Ltd. | T3c Diabetes | 12/25 | 12/26 | | |
NCT05759858: Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 100 | RoW | None of intervention | Second Affiliated Hospital, School of Medicine, Zhejiang University | Hepatocellular Carcinoma | 12/25 | 12/25 | | |
NCT05725590: A Multicenter Randomized Controlled Study of External Pancreatic Duct Stents in Pancreaticoduodenectomy |
|
|
| Recruiting | N/A | 300 | RoW | External pancreatic duct stent, Internal pancreatic duct stent | Second Affiliated Hospital, School of Medicine, Zhejiang University, Ningbo No. 1 Hospital, Huizhou Municipal Central Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Ruian People's Hospital, Linping First People's Hospital | Pancreatic Fistula | 02/26 | 08/26 | | |
